284 related articles for article (PubMed ID: 16004589)
1. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Isaacs JS
Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
[TBL] [Abstract][Full Text] [Related]
2. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update.
Neckers L; Neckers K
Expert Opin Emerg Drugs; 2005 Feb; 10(1):137-49. PubMed ID: 15757409
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F; Kihara K; Neckers L
Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
[TBL] [Abstract][Full Text] [Related]
6. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
7. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HSP90 molecular chaperones: moving into the clinic.
Garcia-Carbonero R; Carnero A; Paz-Ares L
Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
[TBL] [Abstract][Full Text] [Related]
9. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
Hwang M; Moretti L; Lu B
Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
12. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
[TBL] [Abstract][Full Text] [Related]
13. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
14. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
15. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Soga S; Akinaga S; Shiotsu Y
Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
19. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 molecular chaperone inhibitors: are we there yet?
Neckers L; Workman P
Clin Cancer Res; 2012 Jan; 18(1):64-76. PubMed ID: 22215907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
